Synthesis and anti-HIV activity of unusual nucleoside oxanosine derivatives. 1999

Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan.

A series of the oxanosine and carbocyclic oxanosine derivatives were synthesized to evaluate for their anti-HIV activity. Compound 1, 7 and 9 showed weak anti-HIV activities.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012263 Ribonucleosides Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D020298 U937 Cells A human cell line established from a diffuse histiocytic lymphoma (HISTIOCYTIC LYMPHOMA, DIFFUSE) and displaying many monocytic characteristics. It serves as an in vitro model for MONOCYTE and MACROPHAGE differentiation. Cell, U937,Cells, U937,U937 Cell

Related Publications

Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
February 2019, Chemistry & biodiversity,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
December 1998, Indian journal of experimental biology,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
July 2009, Beilstein journal of organic chemistry,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
July 1997, Journal of medicinal chemistry,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
December 2001, Bioorganic & medicinal chemistry letters,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
January 2001, Bollettino chimico farmaceutico,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
January 1991, Nucleic acids symposium series,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
June 1996, Indian journal of experimental biology,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
September 1981, The Journal of antibiotics,
Y Saito, and C Chaicharoenpong, and O Ohno, and E Ichikawa, and S Yamamura, and K Kato, and M Nakamura, and T Ohno, and K Umezawa
January 1981, Nucleic acids symposium series,
Copied contents to your clipboard!